| Unique ID issued by UMIN | UMIN000054424 |
|---|---|
| Receipt number | R000062163 |
| Scientific Title | Phase II clinical trial to examine the efficacy and safety of stereotactic radiotherapy including subclinical regions for pancreatic cancer |
| Date of disclosure of the study information | 2024/05/18 |
| Last modified on | 2024/05/18 07:55:07 |
Phase II clinical trial to examine the efficacy and safety of stereotactic radiotherapy including subclinical regions for pancreatic cancer
Clinical trial of stereotactic radiotherapy including subclinical regions for pancreatic cancer
Phase II clinical trial to examine the efficacy and safety of stereotactic radiotherapy including subclinical regions for pancreatic cancer
Clinical trial of stereotactic radiotherapy including subclinical regions for pancreatic cancer
| Japan |
Pancreatic cancer
| Hepato-biliary-pancreatic medicine | Hepato-biliary-pancreatic surgery | Radiology |
Malignancy
NO
The aim is to examine the efficacy and safety of stereotactic radiotherapy including subclinical region for pancreatic cancer.
Safety,Efficacy
Phase II
1-year locoregional control
Overall survival, Progression-free survival, Distant metastasis-free survival, the acute and late toxicities, the rate of conversion surgery, Disease control rate. Tumor marker kinetics
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
| Device,equipment |
Stereotactic radiotherapy
| 20 | years-old | <= |
| Not applicable |
Male and Female
(1) Borderline resectable or unresectable pancreatic cancer (with or without prior chemotherapy, with or without regional lymph node metastasis)
(2) Histologically or cytologically proven adenocarcinoma
(3) No obvious invasion to gastrointestinal organs such as stomach and duodenum.
(4) Over 20 years old
(5) ECOG PS of 0 or 1
(6) No previous history of surgical resection for pancreatic cancer
(7) No previous history of radiation therapy for abdominal malignancy
(8) Adequate organ functions
(9) Written informed consent
(1) A metallic stent has been inserted in the bile duct and duodenum.
(2) Peritoneal dissemination has been confirmed by peritoneal cytology within 4 weeks prior to enrollment.
(3) Cases with severe complication such as heart disease, renal disease, and hepatic disease
(4) An infectious disease (excluding viral hepatitis) that requires systemic treatment
(5) Other active malignancy at the start of our study
(6) Patients requiring systemic steroids medication or other immunosuppressants
(7) Patients who can' t receive neither iodic drug nor gadolinium because of drug allergy
(8) Cases with severe psychological disorder
(9) Other cases that were judged to be inappropriate for conducting this study
40
| 1st name | Rei |
| Middle name | |
| Last name | Umezawa |
Tohoku University Hospital
Department of Radiation Oncology
980-8574
1-1 Seiryo-machi, Aoba-ku, Sendai
022-717-7312
reirei513@hotmail.com
| 1st name | Rei |
| Middle name | |
| Last name | Umezawa |
Tohoku University Hospital
Department of Radiation Oncology
980-8574
1-1 Seiryo-machi, Aoba-ku, Sendai
022-717-7312
reirei513@hotmail.com
Tohoku University
Tohoku University Graduate School of Medicine
Other
Ethics Committee Tohoku University Hospital
1-1 Seiryo-machi, Aoba-ku, Sendai
022-728-4105
ec@rinri.hosp.tohoku.ac.jp
NO
| 2024 | Year | 05 | Month | 18 | Day |
Unpublished
Preinitiation
| 2024 | Year | 05 | Month | 10 | Day |
| 2024 | Year | 06 | Month | 01 | Day |
| 2029 | Year | 05 | Month | 31 | Day |
| 2024 | Year | 05 | Month | 18 | Day |
| 2024 | Year | 05 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000062163